Finzati - Logo
MESO logo

Mesoblast Limited

MESO • Biotechnology
$17.32
▲ +0.18 (+1.05%)
Current price
EarningsSep 4, 11:07 AM UTC
New financial eventQ4 2026Positive

Mesoblast Limited has reported Q4 2026 financial results

The latest report is predominantly positive and shows an overall improvement in financial performance. Revenue and profitability advanced at a meaningful pace, while the weaker areas should be reviewed in context. The report may attract increased investor attention and price volatility.

Finzati signal
Positive development
Sep 4, 11:07 AM UTC
Improved
+398.38%
Revenue
Improved
+68.02%
Net income
Improved
+59.40%
Free cash flow
Changed
-36.14%
Cash
Improved
-2.18%
Total debt
What changed
↑Revenue increased 398.4% versus the comparable prior period, indicating stronger top-line growth.
↑Net income increased 68.0%, showing improved profitability.
↑Free cash flow increased 59.4%, strengthening cash generation.
↓Cash and short-term investments declined 36.1%.
Based on newly processed financial statements and comparable prior-period data.This is informational analysis, not investment advice.
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Sep 4, 2026, 11:07 AM UTCLast profile update: Sep 4, 2026, 12:09 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$17.32
Change1.05%
Shares Out129.77M
Market Cap$2.25B
Enterprise Value$2.26B
52W Range13.05 - 21.50
Beta0.81
P/E-39.09
P/S18.61
P/B3.95
P/FCF-53.14
EV/Sales18.74

Investment DNA

How strong this company looks for long-term investors

47
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
76/100
Growth Potential
Revenue and expansion
95/100
Price Attractiveness
Cheap or expensive today
49/100
Why this score▼
Positive revenue growth · 58.0%Manageable debt level · 0.22Healthy liquidity · 2.43Weak profitability

Analyst view

Analyst sentiment and price target

MESO
Analyst sentiment
Based on 11 analyst votes · 2026-09-04
64/100
Neutral
Bullish
5
Hold
4
Bearish
2
Price Target
2026-09-04
Low
$39.00
Mean
$39.00
Median
$39.00
High
$39.00

Company Overview

IPO: 1/20/2010
Industry: Biotechnology
P/B i: 3.95
Debt / Equity i: 0.22
Operating Margin: -42.64%
Net Margin: -47.82%
ROE i: -
ROIC: -

Financial Health

Score15 / 20
Debt / Equity: 0.22
Current Ratio: 2.43
Quick Ratio: 2.09
Status: Good

Insider Transactions

Recent executive and insider activity

OBRIEN JAMES MICHAEL
Transaction: 12/23/2025
BUY
Change
+650,000
Price
$2.90
Filing
07/09/2026
Type
BUY
COBLEY LYNETTE ELIZABETH
Transaction: 03/18/2026
OTHER
Change
+200,000
Price
$1.72
Filing
04/29/2026
Type
OTHER
COBLEY LYNETTE ELIZABETH
Transaction: 03/18/2026
OTHER
Change
0
Price
Not reported
Filing
04/29/2026
Type
OTHER